Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMN-1001
- Development stage
- Phase 1
- Lead developer
- Lumen Bioscience
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intranasal
01
Overview
LMN-1001 is an investigational, host-directed intranasal dry powder formulation of recombinant interferon lambda (IFN-λ) developed by Lumen Bioscience. It is designed to activate local innate antiviral defenses in the respiratory tract while limiting systemic exposure. Rather than targeting a specific virus, LMN-1001 stimulates the host's innate immune response, serving as a potential broad-spectrum countermeasure against respiratory viral threats, including emerging infectious diseases. The candidate is produced using Lumen's spirulina-based biomanufacturing platform.
- Other names
- interferon lambdarecombinant interferon lambda
02
Targets
IFNLR1 (Interleukin-28 receptor subunit alpha)IL10RA (Interleukin-10 Receptor)IFNLR (Interferon Lambda Receptor)
Beyond the preview
Go deeper on LMN-1001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMN-1001.